Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

Journal of Clinical Pharmacology

Volumn 39, Issue 11, 1999, Pages 1109-1125

  Yuan, R ^a   Flockhart, D A ^a   Balian, J D ^a  

^a Woodmont II building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; DEXTROPROPOXYPHENE; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NEFAZODONE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; RANITIDINE; RIFAMPICIN; RITONAVIR; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

ANXIETY NEUROSIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; FOOD DRUG INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALPRAZOLAM; ANTI-ANXIETY AGENTS; DATA COLLECTION; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; TRIAZOLAM;

EID: 0033323791     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. Drug metabolism by cytochromes P450 in the liver and small bowel
3. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
4. In vitro metabolism of terfenadine by a purified recombinant fusion protein associated with CYP3A(4) activity and NADPH-P450 reductase
5. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P4503A4 in N-dealkylation and C-hydroxylation
6. Torsades de Pointes occurring in association with terfenadine use
7. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
8. Mechanism of cardiotoxicity of terfenadine
9. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
10. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam
11. Pharmacology of dormicum7 (midazolam) and anexate7 (flumazenil)
12. Drug interactions with amiodarone
13. Alprazolam pharmacokinetics, metabolism, and plasma levels: Clinical implications
14. Alprazolam is another substrate for human cytochrome P450-3A isoforms
15. Ketoconazole inhibiton of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
16. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
17. Coadministration of nefazodone and benzodiazepines: III A pharmacokinetic interaction study with alprazolam
18. Coadministration of nefazodone and benzodiazepines: I Pharmacodynamic assessment
19. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism
20. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
21. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine
22. Fluoxetine impairs clearance of alprazolam but not of clonazepam
23. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
24. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam
25. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects
26. Interaction of propoxyphene with diazepam, alprazolam and lorazepam
27. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction
28. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics
29. Alprazolam pharmacokinetics in women on low-dose oral contraceptives
30. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam
31. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
32. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
33. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo
34. A study of pharmacokinetic interaction between buspirone and alprazolam at Steady state
35. Effect of venlafaxine on the pharmacokinetics of alprazolam
36. Propranolol interactions with diazepam, lorazepam, and alprazolam
37. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam
38. Lack of interaction between disulfiram and alprazolam in alcoholic patients
39. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers
40. Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam
41. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers
42. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
43. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
44. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers
45. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
46. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
47. A potentially hazardous interaction between erythromycin and midazolam
48. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam
49. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin
50. Interaction between midazolam and clarithromycin: Comparison with azithromycin
51. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
52. A pharmacokinetic interaction between roxithromycin and midazolam
53. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance
54. Azithromycin does not alter the effects of oral midazolam on human performance
55. Effect of antidepressents (AD) and ketoconazole (K) on oral midazolam (M) pharamdockinetics (PK)
56. Coadministration of antidepressants (AD) or ketoconazole (K) with oral midazolam (M): Pharmacodynamic (PD) interaction
57. Dose of midazolam should be reduced during diltiazem and verapamil treatments
58. Importance of the interaction of midazolam and cimetidine
59. Interaction of H2-receptor antagonists and benzodiazepine sedation: A double-blind placebo-controlled investigation of the effects of cimetidine and ranitidine on recovery after intravenous midazolam
60. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam
61. Cimetidine and ranitidine increase midazolam bioavailability
62. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam
63. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam
64. Effect of pretreatment with ranitidine on the hypnotic action of single doses of midazolam, temazepam and zopiclone: A clinical study
65. Ranitidine influences the uptake of oral midazolam
66. Effects of antacids on the clinical pharmacokinetics of drugs: An update
67. Interaction between grapefruit juice and midazolam in humans
68. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
69. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin
70. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole
71. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
72. The effect of ingestion time interval on the interaction between itraconazole and triazolam
73. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
74. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
75. A pharmacokinetic drug interaction between erythromycin and triazolam
76. Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin
77. Triazolam kinetics: Interaction with cimetidine, propranolol, and the combination
78. Mechanism for the interaction between triazolam and cimetidine
79. Troleandomycin-triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation
80. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences
81. Coadministration of nefazodone and benzodiazepines: II A pharmacokinetic interaction study with triazolam
82. Enhanced effect of triazolam with diltiazem
83. Diltiazem enhances the effects of triazolam by inhibiting its metabolism
84. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice
85. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine
86. Triazolam is ineffective in patients taking rifampin
87. Effect of different doses of erythromycin on colonic motility in patients with slow transit constipation
88. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
89. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
90. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally